- About ICON8
- About ICON8B
- Information for Patients
- Register interest
- ICON8 Accrual
- ICON8B Accrual
- MRC contacts
- Useful links
- Members area
This website is designed to provide information about the ICON8 Trials Programme encompassing ICON8 and ICON8B for both patients and collaborators.
ICON8 is a randomised three-arm, three stage Gynaecologic Cancer InterGroup (GCIG) phase III trial designed to evaluate the safety and efficacy of dose-dense, dose-fractionated carboplatin-paclitaxel chemotherapy in the treatment of patients with ovarian cancer.
Learn more about ICON8:
ICON8B is a randomised 3-arm, Gynaecologic Cancer Intergroup (GCIG) phase III trial investigating the combination of dose-fractionated chemotherapy and bevacizumab compared to either strategy alone for the first-line treatment of women with newly diagnosed high-risk stage III-IV epithelial ovarian, fallopian tube or primary peritoneal cancer.
Learn more about ICON8B:
The ICON8 Trials Programme December 2016 Newsletter!
ICON8 released the December 2016 Newsletter with important details on the fast approaching start of the ICON8 Primary Analysis, Data Return and TRICON8 Sample Requests.
The ICON8B Trials Team have released the December 2016 Newsletter!
Included is an important message from the ICON8B Chief Investigator and updates to the following:
ICON8 Trials Programme January 2016 Newsletter
The ICON8 Trials Programme recently released the January 2016 newsletter with an update on ICON8 and Tips on how to complete Data Clarification Forms.
ICON8B Trials Programme December 2015 Newsletter
The ICON8 Trials Programme recently released the December 2015 newsletter with an update on TRICON8B Sample Collection and information on urgent queries during the Christmas break.
The newletter is available below:
12th Aug 2015: ICON8 makes way for ICON8B!
After fantastic recruitment in 2014 ICON8 closed to recruitment on the 28th November 2014 with a total of 1566 patients randomised into the trial. We would like to acknowledge all the patients enrolled in the trial and say a huge thank you to all the research staff who have worked on ICON8 over the years, it wouldn’t have been possible without you!
We are very pleased to announce that ICON8B opened to recruitment on 21st July 2015 and to date we are open at 15 sites in England. ICON8B aims to recruit 1170 women from 100+ hospital sites across the UK and Ireland.
We are keen to open as many sites as possible over the summer, please get in touch with the ICON8B trial team if you are unsure what is required of you site before activation.
ICON8 Trials Programme August 2015 Newsletter
The ICON8 Trials Programme recently released the August 2015 newsletter with an update on ICON8B and information on continuing work on ICON8.
The newletter is available below:
ICON8 Trial Update May 2014 Newsletter
ICON8 released the May 2014 Trial Update newsletter with clarifications on the current protocol, an update on TRICON8 and the ICON8 Poster presentation at ASCO 2014.
The Newsletter is available below:
ICON8 at ASCO 2014
We are pleased to report that we have a "Trials in Progress" poster on ICON8 at ASCO this year. If you are at the conference, please come and see us!
Here is a link to the abstract:
The abstract and poster will also be available via the ASCO Virtual Meeting.
1000 patients recruited!
ICON8 has now recruited 1000 patients and looks set to hit the recruitment target of 1485 patients across the 3 arms of the trial by October 2014.
ICON8 Trial Update Autumn 2013 Newsletter
ICON8 released an Autumn 2013 Trial Update newsletter with details of the Stage 1a analysis, Accrual, Translational Research, CRF Completion Guidelines, and a Bevacizumab update. The Newsletter is available below: